Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of SHP465 in Children and Adolescents with ADHD
NCT02578030Phase 1Completed
- Sponsor
- Takeda
- Start
- Oct 2015
- Primary completion
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of SHP465 mixed amphetamine salts in attention deficit hyperactivity disorder (ADHD) (2 arms), sponsored by Takeda. Primary endpoints: Maximum Observed Drug Concentration of Dextroamphetamine, Maximum Observed Drug Concentration of Levoamphetamine and 12 more. Started Oct 2015; status: completed.
02
Drugs
SHP465 mixed amphetamine salts
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT02578030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02578030.